Scholarlink

Purpose <p>A two-drug regimen of palonosetron and dexamethasone is standard for moderately emetogenic chemotherapy (MEC), including oxaliplatin and irinotecan. Current guidelines recommend adding an NK1 receptor antagonist for carboplatin-based or MEC in patients with high-risk features. Given the comparable efficacy of olanzapine, this study evaluated the effectiveness of low-dose olanzapine (OLN, 5&#xa0;mg) combined with ondansetron and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV).</p> Methods <p>In this double-blind, randomized controlled trial, patients initiating oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy were randomized 1:1 to receive OLN or placebo on Days 1–4, with ondansetron and dexamethasone. Randomization was stratified by chemotherapy type and high-risk factors (female aged &lt; 50&#xa0;years). The primary endpoint was total protection (mild/no nausea, no vomiting, and no rescue therapy) within 120&#xa0;h post-chemotherapy. Secondary endpoints included total control, complete response, nausea/vomiting severity, rescue use, adverse events, and patient satisfaction.</p> Results <p>Among 139 evaluable patients, 69 received OLN and 70 received a placebo. Total protection was achieved in 71.0% of OLN patients versus 55.7% with placebo (<i>p</i> = 0.06). Total control was significantly higher with OLN (62.3% vs. 38.6%, <i>p</i> = 0.005). Delayed nausea (grade ≥ 2) occurred less frequently with OLN (13.0% vs. 30.0%, <i>p</i> = 0.015). Complete response and rescue use did not differ between groups. Somnolence rates were similar, but anorexia was less familiar with OLN. Notably, 95.6% of OLN patients preferred to continue the same regimen, compared with 72.9% of placebo recipients (<i>p</i> = 0.001).</p> Conclusion <p>Olanzapine (5&#xa0;mg) combined with ondansetron and dexamethasone was associated with a moderate improvement in total protection and significant improvements in no-nausea and total control rates.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月24日

查看全文
  • Warangkana Harikul,
  • Akarin Nimmannit,
  • Apirom Laocharoenkeat,
  • Pochamana Phisalprapa,
  • Chayanis Kositamongkol,
  • Phurita Thongkijpreecha,
  • Suthinee Ithimakin

摘要

Purpose

A two-drug regimen of palonosetron and dexamethasone is standard for moderately emetogenic chemotherapy (MEC), including oxaliplatin and irinotecan. Current guidelines recommend adding an NK1 receptor antagonist for carboplatin-based or MEC in patients with high-risk features. Given the comparable efficacy of olanzapine, this study evaluated the effectiveness of low-dose olanzapine (OLN, 5 mg) combined with ondansetron and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV).

Methods

In this double-blind, randomized controlled trial, patients initiating oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy were randomized 1:1 to receive OLN or placebo on Days 1–4, with ondansetron and dexamethasone. Randomization was stratified by chemotherapy type and high-risk factors (female aged < 50 years). The primary endpoint was total protection (mild/no nausea, no vomiting, and no rescue therapy) within 120 h post-chemotherapy. Secondary endpoints included total control, complete response, nausea/vomiting severity, rescue use, adverse events, and patient satisfaction.

Results

Among 139 evaluable patients, 69 received OLN and 70 received a placebo. Total protection was achieved in 71.0% of OLN patients versus 55.7% with placebo (p = 0.06). Total control was significantly higher with OLN (62.3% vs. 38.6%, p = 0.005). Delayed nausea (grade ≥ 2) occurred less frequently with OLN (13.0% vs. 30.0%, p = 0.015). Complete response and rescue use did not differ between groups. Somnolence rates were similar, but anorexia was less familiar with OLN. Notably, 95.6% of OLN patients preferred to continue the same regimen, compared with 72.9% of placebo recipients (p = 0.001).

Conclusion

Olanzapine (5 mg) combined with ondansetron and dexamethasone was associated with a moderate improvement in total protection and significant improvements in no-nausea and total control rates.